New Study: CERT2 Predicts Cardiovascular and All-Cause Mortality Beyond PREVENT Risk Calculator

New findings from the US-based Multi-Ethnic Study of Atherosclerosis (MESA) highlight the potential of CERT2 to improve cardiovascular risk assessment in primary prevention.

A new study involving 5,849 participants from the Multi-Ethnic Study of Atherosclerosis (MESA) demonstrates that elevated CERT2 scores are associated with increased risk of cardiovascular and all-cause mortality, even after adjustment for the widely used American Heart Association’s PREVENT Risk Calculator.

The study evaluated the predictive value of CERT2 across different age groups and follow-up periods of 6, 12, and 20 years.

Key Findings

  • Independent predictive value: High CERT2 scores (10–12) were associated with increased cardiovascular and all-cause mortality risk beyond that captured by PREVENT Risk Calculator.
  • Long-term risk prediction: CERT2 identified individuals at increased mortality risk over follow-up periods extending up to 20 years.
  • Evidence in a diverse US population: The findings support the applicability of CERT2 risk prediction in a US-based, multiethnic primary prevention cohort.

  • Across age groups: Associations were observed in younger, middle-aged, and older adults.
  • Potential for improved prevention: CERT2 provides additional information to support more personalized cardiovascular risk assessment and help identify individuals who could benefit from intensified preventive strategies.

Advancing Personalized Cardiovascular Prevention

The findings add to the growing clinical evidence supporting CERT2 as a biomarker-based tool for cardiovascular risk stratification. Importantly, the findings extend the evidence supporting CERT2 risk prediction to a US-based, multiethnic population, demonstrating its predictive value across a diverse populations. The study shows that CERT2 provides prognostic information beyond established clinical risk assessment models, including the PREVENT Risk Calculator.

These results support the potential role of CERT2 as a risk-enhancing biomarker in primary prevention, helping clinicians identify individuals at elevated cardiovascular risk and supporting more targeted lifestyle and pharmacological interventions.

Link to the abstract:

https://www.ahajournals.org/doi/10.1161/circ.154.suppl_1.9443